Scientists have claimed that a protein involved in cancer-promoting cell signaling is also a tumour-suppressor.
Shc pronounced "schick," plays a key role in activating signals which lead to cell proliferation (and cancer) when cells are stimulated, however, also keeps a key component of the signaling pathway tied down and inactive, keeping Erk under wraps when a cell is less active, senior author John Ladbury, Ph.D., professor in MD Anderson's Department of Biochemistry and Molecular Biology, said.
Overexpression of Erk occurs in many types of cancer, including ovarian and prostate cancer and Hodgkin lymphoma, so cellular control of its activity is important.
When the appropriate growth factor receptor is stimulated Erk is activated in the MAP Kinase pathway. It dives into the cell nucleus and turns on a variety of genes, actions that contribute to cancer proliferation, blood vessel production and metastasis when signaling is out of control.
When receptor tyrosine kinases on the cell surface connect with growth factors, they normally send a signal via Shc that sets off a chain of actions leading to Erk activation. Ladbury and colleagues looked at Shc's connections to epidermal growth factor receptor (EGFR) signaling.
Ladbury and his colleagues tested their results in the C.Elegans, a worm model frequently employed in biological research. Both Shc and Erk are greatly similar between humans and the worms.
Experiments showed that Shc blocks Erk function by sequestering it away from the Ras-Raf-Mek MAPK pathway in the worms. Without the Shc-Erk connection, the MAPK pathway is activated, causing excessive Erk activation.
EGFR stimulation not only sets off the normal activation of Erk via Shc and the MAPK pathway, Ladbury said, but also frees Erk for greater availability for activation by breaking the tie to Shc.
The findings have been published in Nature Structural Molecular Biology.